Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study

By Hassanein Mohamed   Hanif Wasim   Malik Waqar   Kamal Ali   Geransar Parnia   Lister Nicola   Andrews Chris   Barnett Anthony  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1367-1374

Informa Healthcare

Access to resources Recommend Favorite

Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany

By Göke R.   Gruenberger J. B.   Bader G.   Dworak M.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 785-789

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness of vildagliptin as add‐on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real‐world setting

By  

JOURNAL OF DIABETES, Vol. 10, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): a randomized trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 18, Iss. 10, 2016-10 ,pp. : 1025-1033

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 581-590

John Wiley & Sons Inc

Access to resources Recommend Favorite